NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
The Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices with effect from 1st October, 2022 under Medical Devices Rules 2017
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Subscribe To Our Newsletter & Stay Updated
